Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences has appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors, adding significant expertise in late-stage development and commercialization. Dr. Bender previously served as CEO of Day One Biopharmaceuticals, leading the company through its approval and launch of OJEMDA and its subsequent $2.5 billion acquisition by Servier.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.